Combined endoscopic stomach reduction and duodenal treatment for obesity with type 2 diabetes
Tests two combined endoscopic procedures in adults with obesity and type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Endoscopic Sleeve Gastroplasty Plus Duodenal pulsENDO for Obese T2DM
Key facts
- Where
- Shatin, Hong KongSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07660445, who can take part
Where in Hong Kong
- Prince of Wales Hospital, The Chinese University of Hong KongShatin, Hong KongTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese University of Hong Kong
- Trial code
- NCT07660445
- Record updated
- 16 September 2026
- Original description
This study is designed to evaluate the efficacy, safety, and mechanisms of combining ESG and pulsENDO procedure in obese patients with T2DMRead full original descriptionShow less
Integrating Duodenal Recellularization Via Electroporation Therapy and Endoscopic Sleeve Gastroplasty as a Novel Approach to Managing Diabesity (DRAGON Study)
This study is designed to evaluate the efficacy, safety, and mechanisms of combining ESG and pulsENDO procedure in obese patients with T2DM
Inclusion: BMI >/= 27kg/m2; Known T2DM; Individualized Metabolic Surgery (IMS) score 25-115; HbA1c <11% (subjects on oral glucose lowering drug(s) or HbA1c <8% (subjects on insulin).
Exclusion: Previous treatment with ReCET, ESG or similar procedure; Previous GI surgery that could preclude the ability to perform ReCET or ESG, or acute gastric and duodenal pathology that increased the risk of ReCET or ESG; Currently taking prescription antithrombotic therapy (e.g., anticoagulant agent) within 10 days prior to study and/or there is a need or expected need to use during the study period; Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics); Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month; Type 1 DM, DM secondary to specific disease or having any history of ketoacidosis; Any inflammatory disease of the gastrointestinal tract such as Crohn's disease; Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study; Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder; Malignancy; Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma); Mental or psychiatric disorder; Drug or alcohol addiction; Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter or known coagulopathy; Fasting C-peptide level <0.5ug/L; Patients with contra-indications to endoscopy; Patients with cirrhosis due to causes other than MASLD; Pregnant or breast feeding; ASA grade IV \& V; Other cases deemed by the examining physician as unsuitable for safe treatment; Refusal to participate.